ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet13204ometendo-13204Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESЭффективность лираглутида в комплексной терапии больных псориазом в сочетании с метаболическими нарушениями: метаанализ наблюдательных и контролируемых исследованийEfficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studieshttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

Коротаева Татьяна Викторовна - д.м.н.

Москва

Tatiana V. Korotaeva - MD, PhD, Professor.

Moscow

tatianakorotaeva@googlemail.comhttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

Трошина Екатерина Анатольевна - д.м.н., чл.-корр. РАН.

Москва

Ekaterina A. Troshina - MD, PhD, Professor.

Moscow

troshina@inbox.ruhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

Лила Александр Михайлович - д.м.н., член-корр. РАН

Москва

Alexander M. Lila - MD, PhD, Professor.

Moscow

sokrat@mail.ruhttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Паневин Тарас Сергеевич - к.м.н.

115522, Москва, Каширское шоссе, 34А

Taras S. Panevin - MD, PhD.

34A, Kashirskoe shosse, Moscow 115522

tarasel@list.ruhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович - д.м.н., акад. РАН.

Москва

Evgeny L. Nasonov - MD, PhD, Professor.

Moscow

cancelar@irramn.ruhttps://orcid.org/0000-0001-5968-2403КорсаковаЮ. Л.KorsakovaYu. L.

Юлия Леонидовна Корсакова - к.м.н.

Москва

Yulia L. Korsakova - MD, PhD.

Moscow

yulkorsakova@bk.ruhttps://orcid.org/0000-0002-4285-0869ГлуховаС. И.GlukhovaS. I.

Глухова Светлана Ивановна - к.ф-м.н.

Москва

Svetlana I. Gluhova - PhD.

Moscow

sveglukhova@yandex.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБУ «НМИЦ эндокринологии им. академика И.И. Дедова» Минздрава РоссииРоссияI.I. Dedov National Medical Research Center of EndocrinologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional EducationRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО Дальневосточный государственный медицинский университет Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; The Far Eastern State Medical UniversityRussian Federation2025030920252227076Copyright © Коротаева Т.В., Трошина Е.А., Лила А.М., Паневин Т.С., Насонов Е.Л., Корсакова Ю.Л., Глухова С.И., 20252025Коротаева Т.В., Трошина Е.А., Лила А.М., Паневин Т.С., Насонов Е.Л., Корсакова Ю.Л., Глухова С.И.Korotaeva T.V., Troshina E.A., Lila A.M., Panevin T.S., Nasonov E.L., Korsakova Y.L., Glukhova S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/13204Обоснование

Обоснование. Псориаз характеризуются высокой частотой сопутствующих метаболических нарушений, включая ожирение и сахарный диабет 2 типа (СД2). Имеются ограниченные данные об эффективности агониста рецептора глюкагоноподобного пептида-1 для лечения метаболических нарушений у пациентов с псориазом.

Цель

Цель. Анализ эффективности лираглутида в комплексной терапии больных псориазом в сочетании с метаболическими нарушениями.

Материалы и методы

Материалы и методы. В базе PubMed проведен поиск исследований по ключевым словам: «psoriasis» и «liraglutide». Найдено 23 публикации, в окончательный анализ вошли 5 исследований с общим размером выборки 52 пациента с псориазом в сочетании с метаболическими нарушениями (СД2 и ожирение). Оценивали влияние лираглутида на распространенность и тяжесть псориаза по динамике индекса площади поражения и тяжести псориаза (PASI), качество жизни по опроснику DLQI и уровень глюкозы плазмы крови натощак, гликированного гемоглобина, индекса массы тела (ИМТ). Результаты представлены в виде средневзвешенной разницы (WMD) и 95% доверительного интервала (ДИ).

Результаты

Результаты. Длительность терапии лираглутидом составила от 8 до 16 нед. Доза лираглутида титровалась от 0,6 мг/сут до 3,0 мг/сут. Показана значимая динамика WMD индексов PASI (-6,95 [95% ДИ -11,59; -2,32]) и DLQI (-6,95 [95% ДИ -11,59; -2,32]), а также ИМТ (-2,97 [95% ДИ -3,58; -2,37]) на фоне терапии лираглутидом. Значимой разницы в уровне глюкозы и гликированного гемоглобина выявлено не было.

Заключение

Заключение. Результаты метаанализа демонстрируют, что использование лираглутида в комплексной терапии псориаза способствует снижению ИМТ, распространенности и тяжести псориаза, а также улучшению качества жизни больных.

BACKGROUND

BACKGROUND: Psoriasis is characterized by a high frequency of comorbid metabolic disorders, including obesity and type 2 diabetes mellitus. There are limited data on the efficacy of glucagon-like peptide-1 receptor agonist for the treatment of metabolic disorders in patients with psoriasis.

AIM

AIM: Analysis of the effectiveness of liraglutide in the complex therapy of patients with psoriasis in combination with metabolic disorders.

MATERIALS AND METHODS

MATERIALS AND METHODS: The PubMed database was searched for studies using the keywords "psoriasis" and "liraglutide". 23 publications were found, the final analysis included 5 studies with a total sample size of 52 patients with psoriasis combined with metabolic disorders (type 2 diabetes mellitus and obesity). The effect of liraglutide on the prevalence and severity of psoriasis was assessed by the dynamics of the lesion area and psoriasis severity index (PASI), quality of life according to the DLQI questionnaire and the level of fasting plasma glucose, glycated hemoglobin, and body mass index. The results are presented as the weighted mean difference (WMD) and 95% confidence interval (CI).

RESULTS

RESULTS: The duration of liraglutide therapy ranged from 8 to 16 weeks. The liraglutide dose was titrated from 0.6 mg/day to 3.0 mg/day. Significant dynamics of the WMD indices PASI (-6.95 [95% CI -11.59; -2.32]) and DLQI (-6.95 [95% CI -11.59; -2.32]), as well as the body mass index (-2.97 [95% CI -3.58; -2.37]) were demonstrated during liraglutide therapy. No significant difference in glucose and glycated hemoglobin levels was found.

CONCLUSION

CONCLUSION: The results of the meta-analysis demonstrate that the use of liraglutide in combination therapy for psoriasis helps to reduce BMI, the prevalence and severity of psoriasis, and improve the quality of life of patients.

псориазлираглутидожирениеметаанализpsoriasisliraglutideobesitymetaanalysisИсточники финансирования. Работа выполнена в рамках фундаментальной научной тематики ФГБНУ НИИР им. В.А. Насоновой №125020501435-8 «Эволюция аксиальных спондилоартритов на основе комплексного динамического изучения молекулярно-биологических, молекулярно-генетических, клинико-визуализационных факторов прогрессирования заболевания, качества жизни, коморбидности и таргетной инновационной терапии»ReferencesArmstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi: https://doi.org/10.1038/nutd.2012.26Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. doi: https://doi.org/10.1038/nutd.2012.26Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835. doi: https://doi.org/10.1016/j.jaad.2006.08.040Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835. doi: https://doi.org/10.1016/j.jaad.2006.08.040Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484-2490. doi: https://doi.org/10.1016/j.jid.2017.07.822Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484-2490. doi: https://doi.org/10.1016/j.jid.2017.07.822Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther. 2020;7(2):271-285. doi: https://doi.org/10.1007/s40744-020-00206-7Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther. 2020;7(2):271-285. doi: https://doi.org/10.1007/s40744-020-00206-7Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol. 2017;44(3):286-291. doi: https://doi.org/10.3899/jrheum.160861Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol. 2017;44(3):286-291. doi: https://doi.org/10.3899/jrheum.160861Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010;59(2):143-145. doi: https://doi.org/10.1016/j.jdermsci.2010.06.004Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010;59(2):143-145. doi: https://doi.org/10.1016/j.jdermsci.2010.06.004Xue K, Liu H, Jian Q, et al. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro--a possible reason for increased severity of psoriasis in patients with a high body mass index. Exp Dermatol. 2013;22(6):406-410. doi: https://doi.org/10.1111/exd.12162Xue K, Liu H, Jian Q, et al. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro--a possible reason for increased severity of psoriasis in patients with a high body mass index. Exp Dermatol. 2013;22(6):406-410. doi: https://doi.org/10.1111/exd.12162Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with comorbid psoriasis and obesity?. Expert Opin Pharmacother. 2019;20(11):1303-1308. doi: https://doi.org/10.1080/14656566.2019.1603294Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with comorbid psoriasis and obesity?. Expert Opin Pharmacother. 2019;20(11):1303-1308. doi: https://doi.org/10.1080/14656566.2019.1603294Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168(5):1124-1127. doi: https://doi.org/10.1111/bjd.12235Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168(5):1124-1127. doi: https://doi.org/10.1111/bjd.12235Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863-872. doi: https://doi.org/10.1080/14656566.2019.1583207Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863-872. doi: https://doi.org/10.1080/14656566.2019.1583207Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73(6):1157-1162. doi: https://doi.org/10.1136/annrheumdis-2012-202812Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73(6):1157-1162. doi: https://doi.org/10.1136/annrheumdis-2012-202812Klingberg E, Björkman S, Eliasson B, Larsson I, Bilberg A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254. doi: https://doi.org/10.1186/s13075-020-02350-5Klingberg E, Björkman S, Eliasson B, Larsson I, Bilberg A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254. doi: https://doi.org/10.1186/s13075-020-02350-5Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017;25(12):2068-2073. doi: https://doi.org/10.1002/oby.21955Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017;25(12):2068-2073. doi: https://doi.org/10.1002/oby.21955Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery [published correction appears in JAMA Surg. 2018;153(7):692]. JAMA Surg. 2017;152(4):344-349. doi: https://doi.org/10.1001/jamasurg.2016.4610Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery [published correction appears in JAMA Surg. 2018;153(7):692]. JAMA Surg. 2017;152(4):344-349. doi: https://doi.org/10.1001/jamasurg.2016.4610Насонов Е.Л., Паневин Т.С., Трошина Е.А. Агонисты рецепторов глюкагоноподобного пептида-1: перспективы применения в ревматологии. // Научно-практическая ревматология. — 2024. — Т.62. — №2. — С.135–144 doi: https://doi.org/10.47360/1995-4484-2024-135-144Nasonov EL, Panevin TS, Troshina EA. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(2):135–144 (In Russ.) doi: https://doi.org/10.47360/1995-4484-2024-135-144Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299-1305. doi: https://doi.org/10.1080/09546634.2021.1882658Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299-1305. doi: https://doi.org/10.1080/09546634.2021.1882658Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: https://doi.org/10.1111/j.1468-3083.2012.04609.xAhern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: https://doi.org/10.1111/j.1468-3083.2012.04609.xBuysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: https://doi.org/10.1111/bjd.12886Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: https://doi.org/10.1111/bjd.12886Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555-559. doi: https://doi.org/10.1111/jdv.12629Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555-559. doi: https://doi.org/10.1111/jdv.12629Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019;150:167-173. doi: https://doi.org/10.1016/j.diabres.2019.03.002Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019;150:167-173. doi: https://doi.org/10.1016/j.diabres.2019.03.002Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161(7):293-296. doi: https://doi.org/10.1016/j.medcli.2023.05.021Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161(7):293-296. doi: https://doi.org/10.1016/j.medcli.2023.05.021Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: https://doi.org/10.3389/fimmu.2023.1148209Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: https://doi.org/10.3389/fimmu.2023.1148209Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512. doi: https://doi.org/10.1124/pr.108.000604Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512. doi: https://doi.org/10.1124/pr.108.000604Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150-152. doi: https://doi.org/10.1111/exd.12081Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150-152. doi: https://doi.org/10.1111/exd.12081Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case. doi: https://doi.org/10.1530/EDM-21-0007Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case. doi: https://doi.org/10.1530/EDM-21-0007Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: https://doi.org/10.1530/EDM-23-0017Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: https://doi.org/10.1530/EDM-23-0017

The authors declare that there are no conflicts of interest present.